Resultados de procura - Alice P. Chen

Limitar resultados
  1. 1
    PARP inhibitors: its role in treatment of cancer

    PARP inhibitors: its role in treatment of cancer por Alice P. Chen

    Publicado 2011
    Ligazón do recurso Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  2. 2
    Molecular Pathways: Targeting PARP in Cancer Treatment

    Molecular Pathways: Targeting PARP in Cancer Treatment por T. Khanh, Alice P. Chen

    Publicado 2012
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  3. 3
    PARP Inhibitor Treatment in Ovarian and Breast Cancer

    PARP Inhibitor Treatment in Ovarian and Breast Cancer por Marcie Weil, Alice P. Chen

    Publicado 2011
    Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  4. 4
    New treatment option for ovarian cancer: PARP inhibitors

    New treatment option for ovarian cancer: PARP inhibitors por Robert Meehan, Alice P. Chen

    Publicado 2016
    Ligazón do recurso Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  5. 5
    PARP Inhibitors in Reproductive System Cancers: Current Use and Developments

    PARP Inhibitors in Reproductive System Cancers: Current Use and Developments por Geraldine O’Sullivan Coyne, Alice P. Chen, Robert Meehan, James H. Doroshow

    Publicado 2017
    Ligazón do recurso Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  6. 6
    Rethinking Oncologic Treatment Strategies with Interleukin-2

    Rethinking Oncologic Treatment Strategies with Interleukin-2 por Brian Ko, Naoko Takebe, Omozusi Andrews, Monish Ram Makena, Alice P. Chen

    Publicado 2023
    Ligazón do recurso Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  7. 7
    Promise and limits of the CellSearch platform for evaluating pharmacodynamics in circulating tumor cells

    Promise and limits of the CellSearch platform for evaluating pharmacodynamics in circulating tumor cells por Lihua Wang, Priya Balasubramanian, Alice P. Chen, Shivaani Kummar, Yvonne A. Evrard, Robert J. Kinders

    Publicado 2016
    Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  8. 8
    Cell surface receptors Ly-9 and CD84 recruit the X-linked lymphoproliferative disease gene product SAP

    Cell surface receptors Ly-9 and CD84 recruit the X-linked lymphoproliferative disease gene product SAP por Joan Sayós, Margarita Martı́n, Alice P. Chen, Marı́a Simarro, Duncan Howie, Massimo Morra, Pablo Engel, Cox Terhorst

    Publicado 2001
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  9. 9
    Advances in using PARP inhibitors to treat cancer

    Advances in using PARP inhibitors to treat cancer por Shivaani Kummar, Alice P. Chen, Ralph E. Parchment, Robert J. Kinders, Jay Ji, Joseph E. Tomaszewski, James H. Doroshow

    Publicado 2012
    Ligazón do recurso Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  10. 10
    GSPE interferes with tau aggregation in vivo: implication for treating tauopathy

    GSPE interferes with tau aggregation in vivo: implication for treating tauopathy por Ismael Santa‐María, Carmen Díaz-Ruiz, Hanna Ksiȩżak-Reding, Alice P. Chen, Lap Ho, Jun Wang, Giulio Maria Pasinetti

    Publicado 2011
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  11. 11
    Aflibercept (VEGF Trap) in Inoperable Stage III or Stage IV Melanoma of Cutaneous or Uveal Origin

    Aflibercept (VEGF Trap) in Inoperable Stage III or Stage IV Melanoma of Cutaneous or Uveal Origin por Ahmad A. Tarhini, Paul Frankel, Kim Margolin, Scott Christensen, Christopher Ruel, Janice Shipe-Spotloe, David R. Gandara, Alice P. Chen, John M. Kirkwood

    Publicado 2011
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  12. 12
    Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors

    Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors por T. Khanh, Deborah Wilsker, Jiuping Ji, Jennifer Zlott, Tomoko Freshwater, Robert J. Kinders, Jerry M. Collins, Alice P. Chen, James H. Doroshow, Shivaani Kummar

    Publicado 2015
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  13. 13
    Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1α), in patients with refractory solid tumors

    Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1α), in patients with refractory solid tumors por Woondong Jeong, Annamaria Rapisarda, Sook Ryun Park, Robert J. Kinders, Alice P. Chen, Giovanni Melillo, Barış Türkbey, Seth M. Steinberg, Peter Choyke, James H. Doroshow, Shivaani Kummar

    Publicado 2013
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  14. 14
    Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium

    Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials co... por Deborah Bradley, Stephanie Daignault, Charles J. Ryan, Robert S. DiPaola, David C. Smith, Eric J. Small, Mitchell E. Gross, Mark N. Stein, Alice P. Chen, Maha Hussain

    Publicado 2010
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  15. 15
    Phase II Clinical and Pharmacokinetic Study of Aflibercept in Patients with Previously Treated Metastatic Colorectal Cancer

    Phase II Clinical and Pharmacokinetic Study of Aflibercept in Patients with Previously Treated Metastatic Colorectal Cancer por Patricia A. Tang, Steven J. Cohen, Christian Kollmannsberger, Georg A. Bjarnason, Kiran Virik, Mary J. MacKenzie, Lillian Lourenço, Lisa Wang, Alice P. Chen, Malcolm J. Moore

    Publicado 2012
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  16. 16
    Phase I Pharmacokinetic and Pharmacodynamic Study of SJG-136, a Novel DNA Sequence Selective Minor Groove Cross-linking Agent, in Advanced Solid Tumors

    Phase I Pharmacokinetic and Pharmacodynamic Study of SJG-136, a Novel DNA Sequence Selective Minor Groove Cross-linking Agent, in Advanced Solid Tumors por Igor Puzanov, Wooin Lee, Alice P. Chen, M. Wade Calcutt, David L. Hachey, W. Vermeulen, Victoria J. Spanswick, Chih‐Yi Liao, John A. Hartley, Jordan Berlin, Mace L. Rothenberg

    Publicado 2011
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  17. 17
    Phase II study of Cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium

    Phase II study of Cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinic... por Ajjai Alva, Susan F. Slovin, Stephanie Daignault, Michael A. Carducci, Robert S. DiPaola, Kenneth J. Pienta, David B. Agus, Kathleen A. Cooney, Alice P. Chen, David C. Smith, Maha Hussain

    Publicado 2010
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  18. 18
    Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV‐PSA) in patients with metastatic androgen‐independent prostate cancer

    Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV‐PSA) in patients with metastatic androgen‐independent prostate cancer por James L. Gulley, Alice P. Chen, William L. Dahut, Philip M. Arlen, Anne Bastian, Seth M. Steinberg, Kwong Y. Tsang, Dennis Panicali, Diane J. Poole, Jeffrey Schlom, J. Michael Hamilton

    Publicado 2002
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  19. 19
    Pharmacological convergence reveals a lipid pathway that regulates C. elegans lifespan

    Pharmacological convergence reveals a lipid pathway that regulates C. elegans lifespan por Alice P. Chen, Kenneth M. Lum, Pablo Lara-González, Daisuke Ogasawara, Armand B. Cognetta, Alan To, William H. Parsons, Gabriel M. Simon, Arshad Desai, Michael Petrascheck, Liron Bar‐Peled, Benjamin F. Cravatt

    Publicado 2019
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  20. 20
    A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation — An NRG Oncology/Gynecologic Oncology Group study

    A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal... por Robert L. Coleman, Michael W. Sill, Katherine M. Bell‐McGuinn, Carol Aghajanian, Heidi J. Gray, Krishnansu S. Tewari, Stephen C. Rubin, Thomas Rutherford, John K. Chan, Alice P. Chen, Elizabeth M. Swisher

    Publicado 2015
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:

Ferramentas de procura: